NEUTRALIZING ANTIBODIES AGAINST HIV-1 BRU AND SF2 ISOLATES GENERATED IN MICE IMMUNIZED WITH RECOMBINANT VACCINIA VIRUS EXPRESSING HIV-1 (BRU) ENVELOPE GLYCOPROTEINS AND BOOSTED WITH HOMOLOGOUS GP160

被引:60
作者
HU, SL
KLANIECKI, J
DYKERS, T
SRIDHAR, P
TRAVIS, BM
机构
[1] Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA
关键词
D O I
10.1089/aid.1991.7.615
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-human immunodeficiency virus type 1 (Anti-HIV-1) antibody response was compared in four groups of mice following inoculation with HIV-1 gp160, with live recombinant vaccinia virus expressing HIV-1 envelope glycoproteins, or with both immunogens in alternate orders for primary or secondary immunizations. Both subunit and recombinant virus immunogens induced similar levels of antibody response following primary immunization. However, after secondary immunization, mice primed with live recombinant virus and then boosted with subunit gp160 immunogen showed significantly higher antibody response than those in the other three groups. Neutralizing antibodies were generated only in this group of mice and were shown to neutralize both the homologous virus (BRU) and a divergent isolate (SF2) of HIV-1. On the other hand, their reactivities to peptide sequences from the principal neutralizing determinant (PND) of gp120 were limited to the BRU isolate, not SF2 or MN, indicating that the cross-neutralizing activities were directed against determinants other than the linear epitope(s) within the PND. These results also indicate that combined immunization by priming with live recombinant virus and boosting with subunit immunogen may be more effective than immunization by either immunogen alone.
引用
收藏
页码:615 / 620
页数:6
相关论文
共 36 条
[1]   LARGE-SCALE PRODUCTION AND PURIFICATION OF A VACCINIA RECOMBINANT-DERIVED HIV-1 GP160 AND ANALYSIS OF ITS IMMUNOGENICITY [J].
BARRETT, N ;
MITTERER, A ;
MUNDT, W ;
EIBL, J ;
EIBL, M ;
GALLO, RC ;
MOSS, B ;
DORNER, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1989, 5 (02) :159-171
[2]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[3]   INDUCTION OF ANTI-HIV NEUTRALIZING ANTIBODIES BY SYNTHETIC PEPTIDES [J].
CHANH, TC ;
DREESMAN, GR ;
KANDA, P ;
LINETTE, GP ;
SPARROW, JT ;
HO, DD ;
KENNEDY, RC .
EMBO JOURNAL, 1986, 5 (11) :3065-3071
[4]   DEVELOPMENT OF A SENSITIVE QUANTITATIVE FOCAL ASSAY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTIVITY [J].
CHESEBRO, B ;
WEHRLY, K .
JOURNAL OF VIROLOGY, 1988, 62 (10) :3779-3788
[5]   SAFETY OF AND IMMUNOLOGICAL RESPONSE TO A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING HIV ENVELOPE GLYCOPROTEIN [J].
COONEY, EL ;
COLLIER, AC ;
GREENBERG, PD ;
COOMBS, RW ;
ZARLING, J ;
ARDITTI, DE ;
HOFFMAN, MC ;
HU, SL ;
COREY, L .
LANCET, 1991, 337 (8741) :567-572
[6]  
COONEY EL, 1990, 6TH INT AIDS C SAN F
[7]   NEUTRALIZATION OF DIVERSE HIV-1 STRAINS BY MONOCLONAL-ANTIBODIES RAISED AGAINST A GP41 SYNTHETIC PEPTIDE [J].
DALGLEISH, AG ;
CHANH, TC ;
KENNEDY, RC ;
KANDA, P ;
CLAPHAM, PR ;
WEISS, RA .
VIROLOGY, 1988, 165 (01) :209-215
[8]   IMMUNIZATION OF CHIMPANZEES CONFERS PROTECTION AGAINST CHALLENGE WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
GIRARD, M ;
KIENY, MP ;
PINTER, A ;
BARRESINOUSSI, F ;
NARA, P ;
KOLBE, H ;
KUSUMI, K ;
CHAPUT, A ;
REINHART, T ;
MUCHMORE, E ;
RONCO, J ;
KACZOREK, M ;
GOMARD, E ;
GLUCKMAN, JC ;
FULTZ, PN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (02) :542-546
[9]   HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 NEUTRALIZATION EPITOPE WITH CONSERVED ARCHITECTURE ELICITS EARLY TYPE-SPECIFIC ANTIBODIES IN EXPERIMENTALLY INFECTED CHIMPANZEES [J].
GOUDSMIT, J ;
DEBOUCK, C ;
MELOEN, RH ;
SMIT, L ;
BAKKER, M ;
ASHER, DM ;
WOLFF, AV ;
GIBBS, CJ ;
GAJDUSEK, DC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (12) :4478-4482
[10]  
HAIGWOOD NL, 1991, VACCINE 90, P313